


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**ENTERING INTO STRATEGIC COOPERATION**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, Chia Tai – Tianqing Pharmaceutical Group Co., Ltd. (“**CT Tianqing**”), a subsidiary of the Group, entered into strategic cooperation with Shenzhen XtalPi Co., Ltd. (深圳晶泰科技有限公司) (“**XtalPi**”), under which, both parties will jointly develop new small molecule drugs against difficult targets for the treatment of malignant tumors.

CT Tianqing has always been at the forefront in the field of research and development of anti-tumor drugs in the industry, while XtalPi is a leading company in applying artificial intelligence technology to research and development of drugs. Under this cooperation, XtalPi will leverage its technological platform of artificial intelligence and high-precision computational chemistry to complete the generation, evaluation and optimization of chemical compounds with a focus on the discovery and optimization of innovative small molecule anti-tumor drugs. Through the strategic cooperation with XtalPi, the Group expects to realize a strong alliance between both parties with complementary advantages, thereby accelerating the discovery of new drugs against difficult anti-tumor targets and developing high-quality oncology drugs to meet the urgent needs for treatment of oncology patients.

**ABOUT XTALPI**

XtalPi is a quantum-physics-based and artificial-intelligence-powered company engaged in research and development of drugs in China with the dedication to achieving industry innovation in research and development of drugs through enhancing the speed, scale, novelty and success rate of research and development of drugs. Its intelligent platform for research and development of drugs integrates cloud-based supercomputing digital tools for research and development with advanced experimental capabilities to form a research and development system under which targeted experiments corroborate high-precision predictions.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 18 March 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*